Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > New Dr Salzman Interview

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Aug 13, 2021 9:54am

87 Views

Post# 33700062

RE:RE:New Dr Salzman Interview

No one can see these interveiws as you have blocked and removed everyone from your site! Maybe copy and paste them on here and CEO!

Amazigh wrote:

PTBailey wrote:

Hey everyone new interview by Drew with Dr. Salzman. Read to the end for his reference to phase 3.

https://claritasinvestors.com/index.php?%2Ftopic%2F1035-salzman-interview-11-august-2021-phase-2 covid%2F&fbclid=IwAR3PwynHlu0l8yH8I66MZbMjJZLGPy0wwQ9AqEYylxUaGC87H9aWbu4sSAc

AWESOME INTERVIEW! Especially the end. We're going to be R-I-C-H, rich!!!